Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
तुलना करने के लिए मीट्रिक्स | EVGN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधEVGNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.6x | −2.1x | −0.4x | |
PEG अनुपात | −0.01 | 0.28 | 0.00 | |
क़ीमत/बुक | −100.8x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 2.1x | 2.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 685.6% | 50.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 12.6% | 6.8% | अनलॉक करें |